BioStem Technologies to Acquire Majority of Assets of Auxocell Laboratories, Inc.
POMPANO BEACH, FLORIDA., March 07, 2023 (GLOBE NEWSWIRE) — BioStem Technologies Inc. (“BioStem” or the “Company”) (OTCQB: BSEM), announced today that it has entered into an Agreement to acquire the majority of the assets of Auxocell Laboratories, Inc. (“Auxocell”), a leading solid tissue processing equipment manufacturer.
Auxocell is the inventor and manufacturer of the Auxocell solid tissue processing equipment, which has revolutionized the field of regenerative medicine. This acquisition will allow BioStem Technologies to expand its product offerings and further establish itself as a leader in the regenerative medicine industry.
Impact on Individuals:
For individuals, the acquisition of Auxocell Laboratories by BioStem Technologies could mean greater access to cutting-edge regenerative medicine technologies. This could potentially lead to improved treatment options for a variety of medical conditions, as well as potentially shorter recovery times and better outcomes for patients undergoing regenerative medicine procedures.
Impact on the World:
On a global scale, the acquisition of Auxocell Laboratories by BioStem Technologies has the potential to elevate the field of regenerative medicine to new heights. By combining their resources and expertise, the two companies can work together to develop innovative solutions for a wide range of medical challenges, ultimately benefiting patients around the world.
Conclusion:
In conclusion, the acquisition of Auxocell Laboratories by BioStem Technologies is a significant development in the field of regenerative medicine. This partnership has the potential to drive advancements in medical technology and improve outcomes for patients both locally and globally. It will be exciting to see what new innovations emerge from this collaboration in the future.
